Back to search results

Image-guided Focal Brachytherapy for Prostate Cancer

This study is testing a new way to treat prostate cancer using image-guided focal brachytherapy. This treatment uses radiation specifically targeted to the cancer. Before treatment, you would have an 18F-DCFPyl PET/CT scan. This special scan helps doctors find the exact location of the cancer within the prostate. The goal is to treat only the cancerous areas, leaving healthy tissue untouched, which may lead to fewer side effects. The study is looking for men aged 18 to 100 with certain types of prostate cancer (adenocarcinoma, Gleason 6-7, and specific clinical stages). The main goal is to see how well the treatment covers the tumor area, measured 30 days after the procedure. The study plans to enroll 20 participants, but its current status is unclear.

Study design
This is an interventional study, meaning participants will receive a specific treatment. It is designed to enroll 20 men.
What's involved
You would undergo an 18F-DCFPyl PET/CT scan and a pre-treatment biopsy. You would then receive focal brachytherapy, with tumor coverage measured 30 days later.
Compensation
Not stated in the trial record.
Follow-up
The primary endpoint is measured 30 days after the brachytherapy procedure.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT03861676

Image-guided Focal Brachytherapy Utilizing Combined 18F-DCFPyl PET/CT

Recruiting
EARLY_PHASE1Ages 18+InterventionalTreatment
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
~20 participants
Updated 2026-02-13 on ClinicalTrials.gov
What's tested:Focal brachytherapy with PSMA PET imaging(18F)DCFPyL

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Percent tumor coverage
Measured over Post-implant Day 30

Conditions

Prostate Cancer

Explore related trials

Prostate Carcinoma

Where it's being run

1 sites across 1 states
Maryland1

Study leadership

  • Daniel Song, MD · PRINCIPAL_INVESTIGATOR · Johns Hopkins University

Who to contact

Daniel Song, MD
[email protected]
(410) 502-5875
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Adenocarcinoma of the prostate
Performance Status \< 2
Clinical stages (not radiographic stage) T1c - T2a, Nx or N0, Mx or M0
Gleason 6-7 cancer
Prostate volume \< 60 cc (if MRI and TRUS have conflicting values, then MRI value will be utilized)
International Prostate symptom score (IPSS) 20 or less
Ability to undergo DCF-Pyl PSMA PET as part of pretreatment staging
Signed study-specific consent form prior to registration

Exclusion

Prior history of pelvic radiation therapy
Major medical or psychiatric illness which, in the investigator's opinion, would prevent completion of treatment and would interfere with follow up.
Implanted device or apparatus which obstruct visibility of the implanted sources on fluoroscopy
Metallic implants, claustrophobia not amenable to medication, or known contraindications to undergoing MR scanning
History of other malignancy diagnosed within the past 3 years

What this trial measures

  • Percent tumor coveragePost-implant Day 30

    Percent coverage of the combined PET-MR based tumor volume achieved when using iRUF intraoperative dosimetry. PET-MR tumor volume D90 will be defined on pre-treatment PET-MR fusion, and dose from seeds will be calculated on post-implant MR/CT (Day \~30); the two volumes will be co-registered to determine tumor volume coverage.